Skip Navigation
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Your Environment. Your Health.

Publication Detail

Title: Generation and Characterization of Patient-Derived Head and Neck, Oral, and Esophageal Cancer Organoids.

Authors: Karakasheva, Tatiana A; Kijima, Takashi; Shimonosono, Masataka; Maekawa, Hisatsugu; Sahu, Varun; Gabre, Joel T; Cruz-Acuña, Ricardo; Giroux, Veronique; Sangwan, Veena; Whelan, Kelly A; Natsugoe, Shoji; Yoon, Angela J; Philipone, Elizabeth; Klein-Szanto, Andres J; Ginsberg, Gregory G; Falk, Gary W; Abrams, Julian A; Que, Jianwen; Basu, Devraj; Ferri, Lorenzo; Diehl, J Alan; Bass, Adam J; Wang, Timothy C; Rustgi, Anil K; Nakagawa, Hiroshi

Published In Curr Protoc Stem Cell Biol, (2020 06)

Abstract: Esophageal cancers comprise adenocarcinoma and squamous cell carcinoma, two distinct histologic subtypes. Both are difficult to treat and among the deadliest human malignancies. We describe protocols to initiate, grow, passage, and characterize patient-derived organoids (PDO) of esophageal cancers, as well as squamous cell carcinomas of oral/head-and-neck and anal origin. Formed rapidly (<14 days) from a single-cell suspension embedded in basement membrane matrix, esophageal cancer PDO recapitulate the histology of the original tumors. Additionally, we provide guidelines for morphological analyses and drug testing coupled with functional assessment of cell response to conventional chemotherapeutics and other pharmacological agents in concert with emerging automated imaging platforms. Predicting drug sensitivity and potential therapy resistance mechanisms in a moderate-to-high throughput manner, esophageal cancer PDO are highly translatable in personalized medicine for customized esophageal cancer treatments. © 2020 by John Wiley & Sons, Inc. Basic Protocol 1: Generation of esophageal cancer PDO Basic Protocol 2: Propagation and cryopreservation of esophageal cancer PDO Basic Protocol 3: Imaged-based monitoring of organoid size and growth kinetics Basic Protocol 4: Harvesting esophageal cancer PDO for histological analyses Basic Protocol 5: PDO content analysis by flow cytometry Basic Protocol 6: Evaluation of drug response with determination of the half-inhibitory concentration (IC50 ) Support Protocol: Production of RN in HEK293T cell conditioned medium.

PubMed ID: 32294323 Exiting the NIEHS site

MeSH Terms: No MeSH terms associated with this publication

Back
to Top